9 February 2021: OIA response | Annual usage of recombinant factor VIII

9 February 2021 

Dear [name and contact details withheld]

REQUEST FOR INFORMATION

Thank you for your request dated 14 January 2021 under the Official Information Act 1982 (OIA) for information relating to recombinant factor VIII. You wrote:

It would be really helpful to know the total units of factor eight currently used in New Zealand annually. Ideally broken down by age.

…I just need to estimate annual usage as measured in IU over a "typical year". 

  • Rurioctocog alfa pegol [Recombinant factor VIII] – Adynovate
  • Moroctocog alfa [Recombinant factor VIII] - Xyntha
  • Octocog alfa [Recombinant factor VIII] - Kogenate FS
  • Octocog alfa [Recombinant factor VIII] (Advate)

 Please find data below to assist with your request. 

Calendar year

2018

2019

2020

Total IUs

21,871,250.00

22,638,750.00

30,004,000.00

Proportion of under 18s

32%

31%

30%

Sum of IUs

 

Over 18

Under 18

2018

14,322,250

7,549,000

2019

15,823,500

6,815,250

2020

20,766,500

9,237,500

Grand total

50,912,250

23,601,750

Sum of patients

 

Over 18

Under 18

2018

  126

  59

2019

  133

  59

2020

  137

  59

Grand total

  396

  177

Please note:

  • A patient’s age is taken as their age at the time of dispensing.
  • Unavoidably, a patient who receives a dispensing at ages 17 and 18 during the same financial year will be counted twice for that financial year (though their units are not double counted). 

Rurioctocog alfa pegol [Recombinant factor VIII] – Adynovate

FYR

Sum of IUs

Sum of
Patient Count

Sum of IUs

Sum of
Patient Count

 

  Under 18

Over 18

2019

  143,000

  <10

686,000

  11

2020

  5,155,500

  35

13,149,000

  62

Moroctocog alfa [Recombinant factor VIII] – Xyntha

 FYR

 Sum of IUs

 Sum of
Patient Count

 Sum of IUs

 Sum of
Patient Count

 

 Under 18

 Over 18

2018

  6,458,250

  53

13,604,250

  121

2019

  5,764,750

  54

14,176,250

  126

2020

  1,785,000

  20

1,735,250

  53

Octocog alfa [Recombinant factor VIII] – Kogenate FS

 FYR

 Sum of IUs

 Sum of
Patient Count

 Sum of IUs

 Sum of
Patient Count

 

 Under 18

 Over 18

2018

  1,090,750

  <10

718,000

  <10

2019

  907,500

  <10

893,000

  <10

2020

  403,250

  <10

342,500

  <10

Octocog alfa [Recombinant factor VIII] – Advate

FYR

Sum of IUs

Sum of
Patient Count

Sum of IUs

Sum of
Patient Count

 

Under 18

Over 18

2019

  -

  -

  68,250

  <10

2020

  1,893,750

  25

  5,539,750

  76

Please note that PHARMAC approaches its assessment of requests for information under the OIA on the basis that, once released, the information becomes publicly available - in other words once we release the information to you it becomes available to any other party in that exact form (whether by you distributing it to others or by virtue of us receiving the same request from a different third party).

We have made some adjustments to the data provided where patient totals are equal to or less than 10 (displayed as <10) as we consider this is necessary to protect the privacy of those patients (section 9(2)(a)).

As required under the OIA, we also considered whether, in the circumstances, the withholding of this information was outweighed by other considerations which render it desirable, in the public interest, to make this information available.  In this case we did not consider that the public interest outweighed the reasons for withholding the information.

Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.

We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.

Yours sincerely

Rachel Read
Manager, Policy and Government Services